It is very uncertain whether meropenem changes neurological developmental impairment maximum compared with standard care (very low certainty).
It is very uncertain whether meropenem changes necrotising enterocolitis maximum compared with standard care (very low certainty).
It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).
It is very uncertain whether vancomycin plus gentamicin changes serious adverse events maximum compared with vancomycin plus aztreonam (very low certainty).
It is very uncertain whether vancomycin plus gentamicin changes necrotising enterocolitis maximum compared with vancomycin plus aztreonam (very low certainty).
It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with flucloxacillin and gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes all‐cause mortality maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes serious adverse events maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes circulatory support maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes nephrotoxicity maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes all‐cause mortality maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin changes serious adverse events maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin changes nephrotoxicity maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes serious adverse events maximum compared with penicillin plus gentamicin (very low certainty).